11/21
04:17 am
dsnky
Metastatic Triple-Negative Breast Cancer (mTNBC) Pipeline Landscape Research 2024: Comprehensive Insights About 10+ Companies and 12+ Drugs [Yahoo! Finance]
Low
Report
Metastatic Triple-Negative Breast Cancer (mTNBC) Pipeline Landscape Research 2024: Comprehensive Insights About 10+ Companies and 12+ Drugs [Yahoo! Finance]
11/13
08:00 am
dsnky
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
Medium
Report
Daiichi Sankyo to Showcase TURALIO® Research in Patients with Tenosynovial Giant Cell Tumor at CTOS
11/12
02:00 am
dsnky
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
Low
Report
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
11/10
07:07 pm
dsnky
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
Low
Report
Alteogen enters into an Exclusive License Agreement to Develop and Commercialize Subcutaneous ENHERTU® Enabled by Alteogen's Hybrozyme™ Technology
11/8
08:00 am
dsnky
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
Low
Report
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
11/8
05:28 am
dsnky
AstraZeneca's China-Fueled Plunge May Be Difficult to Shake Off [Yahoo! Finance Canada]
Low
Report
AstraZeneca's China-Fueled Plunge May Be Difficult to Shake Off [Yahoo! Finance Canada]
11/1
08:40 am
dsnky
Daiichi Sankyo Company And 2 Other Stocks Considered To Be Trading Below Fair Value Estimates [Yahoo! Finance]
Low
Report
Daiichi Sankyo Company And 2 Other Stocks Considered To Be Trading Below Fair Value Estimates [Yahoo! Finance]
10/30
08:00 am
dsnky
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
Low
Report
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
10/29
10:41 am
dsnky
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL [Yahoo! Finance]
Low
Report
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL [Yahoo! Finance]
10/29
10:35 am
dsnky
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL
Low
Report
American Regent introduces FDA-approved Epinephrine Injection, USP in 30 mL
10/25
08:54 am
dsnky
Orano Announces Leadership Transition in Orano Med [Yahoo! Finance]
Low
Report
Orano Announces Leadership Transition in Orano Med [Yahoo! Finance]
10/24
09:19 am
dsnky
Latest AMRA Medical Research in Muscle & Nerve Demonstrates The Utility of MRI-based Biomarkers In Inflammatory Myopathies [Yahoo! Finance]
Low
Report
Latest AMRA Medical Research in Muscle & Nerve Demonstrates The Utility of MRI-based Biomarkers In Inflammatory Myopathies [Yahoo! Finance]
10/7
09:40 am
dsnky
Antibody Drug Conjugates Market Size Potential to Reach USD 39 Billion by 2032 By IMIR Market Research Pvt. Ltd. [Yahoo! Finance]
Neutral
Report
Antibody Drug Conjugates Market Size Potential to Reach USD 39 Billion by 2032 By IMIR Market Research Pvt. Ltd. [Yahoo! Finance]
10/1
02:00 am
dsnky
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
Low
Report
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
9/23
02:11 am
dsnky
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial [Yahoo! Finance]
Medium
Report
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial [Yahoo! Finance]
9/23
02:00 am
dsnky
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
Medium
Report
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
9/20
05:09 am
dsnky
NHS England to offer Daiichi Sankyo's quizartinib for AML [Yahoo! Finance]
Low
Report
NHS England to offer Daiichi Sankyo's quizartinib for AML [Yahoo! Finance]
9/18
07:17 am
dsnky
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance [Seeking Alpha]
Low
Report
Daiichi Sankyo: Showing No Signs Of Slowing Down ADC Dominance [Seeking Alpha]
9/18
06:04 am
dsnky
Daiichi Sankyo and MSD's ADC improves progression-free survival in NSCLC trial [Yahoo! Finance]
Low
Report
Daiichi Sankyo and MSD's ADC improves progression-free survival in NSCLC trial [Yahoo! Finance]
9/16
05:28 am
dsnky
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours [Yahoo! Finance]
Low
Report
Daiichi Sankyo posts positive DS-9606 clinical trial results in solid tumours [Yahoo! Finance]
9/15
10:13 pm
dsnky
ESMO 2024: TROP2-directed ADCs show promise in recurrent gynecological cancers [Yahoo! Finance]
Low
Report
ESMO 2024: TROP2-directed ADCs show promise in recurrent gynecological cancers [Yahoo! Finance]
9/15
08:45 am
dsnky
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
Low
Report
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
9/14
03:04 am
dsnky
AstraZeneca, Roche cut at Deutsche after trial readouts for key drugs [Seeking Alpha]
Low
Report
AstraZeneca, Roche cut at Deutsche after trial readouts for key drugs [Seeking Alpha]
9/13
10:00 am
dsnky
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
Low
Report
ENHERTU® Showed Substantial Clinical Activity in Patients with HER2 Positive Metastatic Breast Cancer and Brain Metastases
9/9
01:50 pm
dsnky
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial
Medium
Report
Datopotamab Deruxtecan Showed Median Overall Survival of 14.6 Months in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer in TROPION-Lung01 Phase 3 Trial